18 May 2022 | BST (UTC+1)

Genevive Hernandez

Senior Director, Clinical Biomarkers, Clinical Research and Development
IGM Biosciences
Genevive Hernandez
Genevive Hernandez-Pantua is Senior Director and Head of Clinical Biomarkers at IGM Biosciences, a biotechnology company pioneering the use of novel engineered multivalent and multispecific therapeutics. She was previously at Genentech, where she completed her postdoctoral studies on the interplay between angiogenesis and tumor immunity, and then became the Biomarker Lead for multiple trials of the breakthrough cancer immunotherapies atezolizumab (anti-PDL1 Ab) and mosunetuzumab (CD20xCD3 bispecific Ab). She obtained her PhD in Biomedical Sciences from the University of Massachusetts Medical School and BS in Molecular Biology and Biotechnology from the University of the Philippines-Diliman. She also received additional training on infectious diseases and public health at the Research Institute for Tropical Medicine in the Philippines. Dr. Hernandez-Pantua has over 20 years of experience in preclinical, translational, and clinical research encompassing vaccine development, cellular immunology, and immuno-oncology. Her passion is to develop immune-based therapies with transformative benefit.


No data was found

Other Speakers

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Download Brochure

Full details regarding the Immuno Series UK are available for download in the Conference Brochure